SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorDana-Farber Cancer Institute

About this trial

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS.

The interventions involved in this study are:

* SL-401 * Azacitidine * Venetoclax

None

None

72 Participants

are divided into 2 treatment groups

City of Hope91010, DuarteCalifornia, United States

Dana Farber Cancer Institute02215, BostonMassachusetts, United States

MD Anderson Cancer Center77030, HoustonTexas, United States

Dana-Farber Cancer Institute

Lead sponsor

Stemline Therapeutics, Inc.

Collaborator